Mike Sharma: Adding Antiplatelets to Anticoagulation in AF Increases Harm Without Benefit
Mike Sharma, Senior Scientist at Population Health Research Institute, reposted from JAMA Neurology on LinkedIn:
”Adding antiplatelets to anticoagulation in the setting of AF results in hazard without benefit. Now we’ll established in multiple studies. Where we lack data is in short term use following a cerebrovascular event that may be atherosclerotic in origin in patients with coexisting AF.”
Quoting JAMA Neurology‘s post:
”Editorial: The ATIS-NVAF trial shows adding antiplatelet therapy to OAC in stroke patients with AF and atherosclerotic disease increases major bleeding without significant reduction in ischemic events.”
Read the full article here.
Title: Anticoagulation and Antiplatelet Therapy in Patients With Atrial Fibrillation and Atherosclerosis
Authors: Richard A. Bernstein, Lauren E. Previch
Stay updated with Hemostasis Today.
-
May 18, 2026, 08:12Perioperative Anticoagulation Management Isn’t a Checklist – Thrombosis Canada
-
May 18, 2026, 08:04Sophia Delicou: Iron Chelation Plateaus and Organ-Specific Iron Distribution in β-Thalassemia
-
May 18, 2026, 08:04Comprehensive Analysis of Patients With Prior Negative Genetic Testing for Wilson Disease – JHEP Reports
-
May 18, 2026, 08:022026 ITP Annual Patients’ Convention – ITP Support Association
-
May 18, 2026, 08:02Thomas Rocco Jr.: World Hypertension Day and the Future of Cardiovascular Prevention
-
May 18, 2026, 05:02Sandeep De: Omicron Infection Confirmed to Raise Blood Clot Risk for 6 Months
-
May 18, 2026, 04:52Abdessamia Gandoul: EHA Bedside Hematology Rapid Reference Guide Is Now Live
-
May 18, 2026, 04:41Hisam Siddiqi: Revisiting the Classic List of Risk Factors for Venous Thromboembolism
-
May 18, 2026, 04:36Luma Mahairi: Computational Insights into the Protein S Complex and the Future of Precision Hematology